上海金畔生物科技有限公司为生命科学和医药研发人员提供生物活性分子抑制剂、激动剂、特异性抑制剂、化合物库、重组蛋白,专注于信号通路和疾病研究领域。
NCT-505 纯度: 98.41%
NCT-505 是一种有效的,选择性的乙醛脱氢酶 (aldehyde dehydrogenase (ALDH1A1)) 抑制剂,IC50 值为 7 nM,对 hALDH1A2,hALDH1A3,hALDH2,hALDH3A1 的抑制作用较弱,IC50 值分别为 >57,22.8,20.1,>57 μM。
NCT-505 Chemical Structure
CAS No. : 2231079-74-4
规格 | 价格 | 是否有货 | 数量 |
---|---|---|---|
5 mg | ¥5000 | In-stock | |
10 mg | ¥8200 | In-stock | |
50 mg | 询价 | ||
100 mg | 询价 |
* Please select Quantity before adding items.
NCT-505 相关产品
•相关化合物库:
- Bioactive Compound Library Plus
- Metabolism/Protease Compound Library
- Anti-Cancer Compound Library
- Glutamine Metabolism Compound Library
- Anti-Cancer Metabolism Compound Library
生物活性 |
NCT-505 is a potent and selective aldehyde dehydrogenase (ALDH1A1) inhibitor, with an IC50 of 7 nM, and weakly inhibits hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 (IC50s, >57, 22.8, 20.1, >57 μM). |
IC50 & Target |
IC50: 7 nM (ALDH1A1), >57 μM (hALDH1A2), 22.8 μM (hALDH1A3), 20.1 μM (hALDH2), >57 μM (hALDH3A1)[1] |
||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
体外研究 (In Vitro) |
NCT-505 (Compound 86) is a potent and selective aldehyde dehydrogenase (ALDH1A1) inhibitor, with an IC50 of 7 nM, and weakly inhibits hALDH1A2, hALDH1A3, hALDH2, hALDH3A1 (IC50s, >57, 22.8, 20.1, >57 μM). NCT-505 has no obvious inhibitory effec on 5-hydroxyprostaglandin dehydrogenase (HPGD) and type-4 hydroxysteroid dehydrogenase (HSD17β4) (IC50, >57 μM). Moreover, NCT-505 shows potent cellular activities, reducing the viability of OV-90 cells with an EC50 of 2.10-3.92 μM. NCT-505 is also cytotoxic to SKOV-3-TR cells, with IC50s of 1, 3, 10, 20, 30 μM, respectively, in the titration assay[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
||||||||||||
分子量 |
521.61 |
||||||||||||
Formula |
C27H28FN5O3S |
||||||||||||
CAS 号 |
2231079-74-4 |
||||||||||||
运输条件 |
Room temperature in continental US; may vary elsewhere. |
||||||||||||
储存方式 |
|
||||||||||||
参考文献 |
|
Cell Assay [1] |
Cells are harvested, and an equal volume of first compound (NCT-505 or paclitaxel (Taxol)) at the indicated concentration or vehicle DMSO (final DMSO concentration is the same in all conditions) is added to the cell suspension before dispensing. Cells are dispensed into 384-well, white, TC-treated plates at a density of 3000 cells/well in a volume of 30 μL of growth media/well using a Multidrop Combi dispenser. Immediately after dispensing, the second compound (ALDH1A1 inhibitor or paclitaxel) and control solutions (92 nL) are transferred using a pintool. Plates are covered with a breathable seal and incubated for 4 days at 37°C, 5% CO2, 85% RH followed by addition of 20 μL of CellTiter-Glo. After a ∼30 min incubation at rt, samples are analyzed for luminescence intensity using a ViewLux high-throughput CCD imager equipped with clear filters. Pinned compounds are tested as 16-point dilution series, with concentrations ranging from 30.7 μM to 70.1 nM for ALDH1A1 inhibitors (NCT-505, etc.) or 31.7 μM to 0.034 nM for paclitaxel, in triplicate. Data are normalized to positive control bortezomib (1 μM final) and neutral control DMSO[1]. 上海金畔生物科技有限公司 has not independently confirmed the accuracy of these methods. They are for reference only. |
---|---|
参考文献 |
|
所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务